linjc16/ctgov huggingface dataset:
Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
Primary Purpose: Evaluate the prevalence and incidence of HEV infection in MHD patients. Compare differences of the prevalence and incidence between the MHD patients and the control. . Secondary purpose: Analyze risk factors of HEV infection.

Detailed Description
-----------------
This is an Epidemiological study manufactured by Xiamen University. The primary purpose of this study is to evaluate the prevalence and incidence of HEV infection in MHD patients and to compare differences between the MHD patients and the control. The secondary purpose of this study is to analyze risk factors of the infection of HEV. There are two phases in this study. The first phase is a cross-sectional study. Approximately 200 MHD patients will be enrolled in MHD patient group, followed by control group's enrollment according to the age and gender of the MHD patient group. Blood samples and questionnaire were got at this time. Secondly, 100 enrolled volunteers in each group who is negative for HEV-IgM、HEV-IgG、HEV RNA will be introduced into the cohort study. The MHD patient group will been taken blood samples at an interval of 3 month until the 12th month after the first phase, however, the control group only need one blood sample at 12th month.

Conditions
-----------------
Hepatitis E Virus Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Maintenance hemodialysis patients and healthy people as control Can understand the study progress, willing to sign the informed consent and participate the study Exclusion Criteria: Has received HEV vaccines
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group, disease history<br>people who didn't have disease history of Maintenance Hemodialysis | |
| The MHD patient group, diseases history<br>Maintenance Hemodialysis Patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of HEV infection | number and rate of participants with abnormal laboratory values in the MHD patients and the control; | up to 1 year after enrollment | 
| new-infection rate of HEV infection | number and rate of the participants who's baseline laboratory value is normal and change to abnormal during the follow-up in the MHD patients and the control | up to 1 year after enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk factors of HEV infection | the odd ratio(OR) and 95%CI of the factors such as age gender for HEV infection in the MHD patients and the control | up to 1 year after enrollment |
The Effect of Nasal Cannulae During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy

Study Overview
=================
Brief Summary
-----------------
At our institute,during the first 2 hour postoperative, we used to give supplement oxygen via face mask in patient having lung resection surgery. After then if the patient is fine, we'll replace the face mask with nasal cannular untie the next morning. We hypothesized that oxygen mask can be replace by nasal cannular without any hypoxia.

Official Title
-----------------
The Effect of Nasal Cannulae During the First 2 Hours Postoperative in Patient

Conditions
-----------------
Hypoxia, Post Pulmonary Resection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >/= 18 years old Patient undergoing lobectomy or pneumonectomy or wedge resection ASA 1-3 Preoperative oxygen saturation < 95 % Exclusion Criteria: Cannot communication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Oxygen cannular<br>After lung resection surgery,every patient will received supplementary oxygen 5 L/minutes via oxygen cannular for 120 minutes | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxygen saturation | We continuously monitor oxygen saturation and record every 5 minutes for 30 minutes postoperative. | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of hypoxemia |  | 3 days postoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post Pulmonary Resection, hypoxemia
Quality of Life in Adult Patients With Severe Haemophilia in Turkey

Study Overview
=================
Brief Summary
-----------------
The primary aim of this study is to evaluate the overall quality of life in adult patients with severe haemophilia (an inherited bleeding disorder affecting mainly men) in Turkey and to assess the impact of certain disease and drug related factors (treatment modality, presence of viral disease, inhibitor, etc.) on the quality of life.

Detailed Description
-----------------
Haemophilia is an inherited bleeding disorder affecting one in 10000 male births worldwide. People with severe haemophilia usually suffer from recurrent life threatening bleeds (e.g. into the brain, digestive system or abdomen) and/or disabling degenerative disease of weight bearing joints (e.g. knees, elbows and ankles)resulting from haemorrhage into the joints. Daily activities of people with haemophilia has been shown to be dramatically hampered by the resultant joint damage. Evaluation of quality of life issues in people with severe haemophilia would help to create awareness of their problems and limitations. This would also set up the scene for developing policies to improve the treatment options/facilities and social life of the patients. Current study aims to assess the quality of life of adult patients with severe haemophilia in a developing country (Turkey) by using a validated Quality of Life Questionnaire (Turkish version of Haem-A-QoL).

Official Title
-----------------
A Nationwide Multicenter Study on the Quality of Life in Adult Patients With Severe Haemophilia in Turkey

Conditions
-----------------
Haemophilia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age equal or greater than 18 years male gender factor VIII or IX level equal or below 1% patients that are willing to participate and have given a written consent Exclusion Criteria: age less than 18 years females factor levels above 1%

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
severe haemophilia, quality of life
Human Intervention Study With Calcium Phosphate and Vitamin D

Study Overview
=================
Brief Summary
-----------------
The study was conducted to investigate the effect of vitamin d3 alone and in combination with calcium phosphate on bone metabolism and further physiological parameters in healthy subjects. It is postulated that calcium phosphate beneficially influences the bone specific action of vitamin d3.

Official Title
-----------------
The Effect of Vitamin D3 Alone and in Combination With Calcium Phosphate on Bone Metabolism in Healthy Adults

Conditions
-----------------
Healthy Subjects

Intervention / Treatment
-----------------
* Dietary Supplement: calcium phosphate
* Dietary Supplement: vitamin d
* Dietary Supplement: calcium phosphate and vitamin d
* Other: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy subjects Exclusion Criteria: pregnancy, lactation intake of dietary supplements

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: calcium phosphate<br> | Dietary Supplement: calcium phosphate<br>* 20 subjects consume for 8 weeks a bread enriched with calcium phosphate [1g calcium/d]<br>|
| Experimental: vitamin d<br> | Dietary Supplement: vitamin d<br>* 20 subjects consume for 8 weeks a bread with vitamin d3 [10µg/d]<br>|
| Experimental: calcium phosphate and vitamin d<br> | Dietary Supplement: calcium phosphate and vitamin d<br>* 20 subjects consume for 8 weeks a bread enriched with calcium phosphate [1g calcium/d] and vitamin d3 (10µg/d]<br>|
| Placebo Comparator: placebo<br> | Other: placebo<br>* All participants consume two weeks before intervention a bread without calcium an vitamin d.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bone resorption and bone formation markers in blood and urine |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| concentration of minerals in blood, stool and urine |  | 8 weeks | 
| blood lipids |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
calcium phosphate, vitamin d3, bone metabolism, human study
Antiemetic Efficacy and Safety of Dexamethasone in Obstetric Surgical Patients

Study Overview
=================
Brief Summary
-----------------
This is a randomised controlled double blinded clinical trial to determine the antiemetic efficacy and safety of either 8 mg of dexamethasone or normal saline (placebo) given 1 hour before induction of either spinal or general anaesthesia in 2 arms (of 150 each).

Official Title
-----------------
Antiemetic Efficacy and Safety of Dexamethasone in Patients Undergoing Caesarean Sections at Mulago Hospital

Conditions
-----------------
Postoperative Nausea and Vomiting

Intervention / Treatment
-----------------
* Drug: dexamethasone
* Other: normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all woman above 18 years old presenting for obstetric surgery and have consented to study. Exclusion Criteria: refusal/unable to consent, younger than 18 years old, hypertensive, diabetic, preeclamptic, sepsis, ASAIIIE plus.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: dexamethasone 8mg<br> | Drug: dexamethasone<br>* single Bolus dose of dexamethasone 8mg<br>|
| Placebo Comparator: normal saline<br> | Other: normal saline<br>* 2 ml 0.9% saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| presence of post nausea and or vomiting |  | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| perianal itching |  | 24 hours | 
| hyperglycemia |  | 24 hours | 
| hypertension |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PONV
24-hour Blood Pressure Dynamics and Autonomic Adrenergic Regulation in Type 2 Diabetics

Study Overview
=================
Brief Summary
-----------------
Autonomic neuropathy is a common complication of type 2 diabetes mellitus. Symptoms from cardiovascular autonomic neuropathy include, dizziness, orthostatic hypotension and insufficient heart rate and blood pressure (BP) regulation during physical exertion. The degree of cardiovascular autonomic neuropathy is most commonly measured as cardiac autonomic neuropathy based on at least two abnormal cardiac reflex tests, which primarily measures parasympathetic indices of the autonomic nervous system (ANS). Few measures are available for quantifying the sympathetic/adrenergic branch of the ANS. Circadian changes in BP is a documented measure of BP variability, regulated centrally by a multitude of centers. A growing number of studies indicate that a diminished BP variability is associated with increased cardiovascular risk and injury. The ANS plays a pivotal role in the execution of these circadian BP changes, mainly through sympathetic adrenergic nerve fibers Few studies have investigated the applicability of 24-hour indices as predictor for autonomic adrenergic dysfunction. No previous studies have investigated the association between clinical markers of adrenergic function, and 24-hour blood pressure indices in type 2 diabetes.

Official Title
-----------------
24-hour Blood Pressure Dynamics and Autonomic Adrenergic Regulation in Type 2 Diabetics

Conditions
-----------------
Diabetes Mellitus, Type 2, Polyneuropathy Diabetes, Autonomic Neuropathy, Diabetic Neuropathies, Diabetic Complications Neurological

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes Normal 12-lead ECG Exclusion Criteria: Significant cardiovascular, muscular, lung, kidney or psychiatric disease Pregnancy Malignant disease, HIV, alcoholism or drug abuse Parkinson disease Ischemic heart disease Vital medicine that can affect the autonomic nervous system

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Type 2 diabetics | |
| Healthy controls<br>Matched healthy controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 24 hour Blood Pressure | Day/night blood pressure ratio. Day time standard deviation and average real time variation | 0 | 
| Autonomic adrenergic measure | Valsalva maneuver - Phase 2Late, Pressure recovery time, Baroreceptor sensitivity, Phase 4 rise. Head up tilt test - Blood pressure dip ratio | 0 |
Ovarian Screening Study

Study Overview
=================
Brief Summary
-----------------
The objectives of this study are: To identify women at increased risk for developing ovarian cancer To detect ovarian cancers at an early stage To investigate the role of tumor membrane fragments as tumor markers for early ovarian carcinoma

Detailed Description
-----------------
In the year 2001 approximately 23,400 women in the USA are expected to be diagnosed with ovarian carcinoma and 13,900 will die of the disease. This means that within the USA more women die annually from ovarian cancer than all other gynecologic malignancies combined. Within the Commonwealth of Kentucky approximately 250 women per year develop ovarian carcinoma. Survival for patients with ovarian cancer is directly related to the stage of disease at diagnosis. Unfortunately, the majority of women present with advanced disease (Stage III and IV) and most of these patients will die of the disease. The aim of screening for ovarian cancer is to reduce the morbidity and mortality by detecting the disease at an early stage since ovarian cancer detected when disease is confined to the ovary (Stage I) is associated with a dramatically improved 5-year survival. Disease confined to the ovary may be cured in over 90% of patients, in some cases without the need for chemotherapy.

Official Title
-----------------
The University of Louisville Ovarian Screening Study

Conditions
-----------------
Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asymptomatic women over the age of 45 with one or both ovaries. Women over the age of 25 with one or both ovaries and any of the following: A personal history of breast, colon or endometrial cancer or breast cancer gene (BRCA) 1 or 2 positive First-degree relative (mother, sister, daughter) with ovarian or breast cancer Two family members with either breast and/or ovarian cancer Mother, sister, daughter, grandparent with a positive BRCA1 or BRCA2 genetic test result. Past use of fertility drugs such as Clomid or Pergonal for more than a year. Exclusion Criteria: Women who are symptomatic of ovarian cancer

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ovarian Cancer
Willingness to Pay for Patient-centred Care

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the monetary value of patient-centrednes in health care by determining a willingness-to-pay for more patient-centredness care for both patients and health insurers

Detailed Description
-----------------
We perform our study in the area of fertility care, as it is known that infertile patients suffer from a high physical and physiological burden during treatment and could especially benefit from patient-centred care. Moreover, previous studies have clearly identified the concept of patient-centred fertility care and have shown that improvement is needed.

Official Title
-----------------
Identifying Patients' and Healht Insurers' Preferences Regarding Patient-centred Care by Determining Their Willingness-to-pay for Patient-centred Care

Conditions
-----------------
Willingness-to-pay, Patient-centredness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing MAR-treatment (ovulation induction, intra-uterine inseminations, in vitro fertilization, or intra-cytoplasmic sperm injection) All healthcare purchasers working at one of the 5 large Dutch health insurer companies. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Willingness-to-pay for patient-centred care | A willingness-to-pay for patient-centred care for both patients and health insurers | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Willingness-to-pay, Patient-centredness, Health insurers, Fertility care
Breethe Abiomed Recovery regisTry (BART)

Study Overview
=================
Brief Summary
-----------------
The BART Registry intended to utilize observational data of the Abiomed Breethe OXY-1 System™ in real-world settings to drive best practice usage patterns, serve as a tool to measure and improve the quality of patient care and as a resource to inform us on the design of future studies.

Official Title
-----------------
Breethe Abiomed Recovery regisTry (BART)

Conditions
-----------------
Cardiopulmonary Bypass, ARDS, Heart Failure

Intervention / Treatment
-----------------
* Device: Breethe Oxy-1 System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all adult subjects supported with Breethe Oxy-1 System Exclusion Criteria: subjects under 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Breethe Oxy-1 System|To pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass with Breethe Oxy-1 System|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival up to the hospital discharge |  | Up to the hospital discharge, an average of 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breethe Oxy-1 System, Extracorporeal Membrane Oxygenation, Cardiopulmonary bypass, ARDS, Heart failure
Natural History of Asymptomatic Superior Mesenteric Arterial Stenosis.

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to evaluate asymptomatic superior mesenteric artery (SMA) stenosis prognosis according to the presence of coeliac artery (CA) and/or inferior mesenteric artery (IMA) associated stenosis.

Detailed Description
-----------------
BACKGROUND: The benefit of preventive treatment for SMA stenosis remains uncertain. The latest guidelines remain unclear given the lack of data in the literature.

Official Title
-----------------
Natural History of Asymptomatic Superior Mesenteric Arterial Stenosis Depends on Celiac and Inferior Mesenteric Arteries Status.

Conditions
-----------------
Stenosis

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the presence of coeliac artery (CA) and/or inferior mesenteric artery (IMA) associated stenosis. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patient with isolated SMA stenosis<br>patient with isolated SMA stenosis on initial scanner | Other: No intervention<br>* No intervention<br>|
| patient with both SMA stenosis and CA or/and IMA stenosis<br>patient with both SMA stenosis and CA or/and IMA stenosis on initial scanner | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of mesenteric disease defined as acute mesenteric ischemia or chronic mesenteric ischemia. |  | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SMA, Stenosis, Stenosis on scanner